-
Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO
•
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering (IPO) of 173 million shares by its consumer health spin-off company Kenvue to the New York Stock Exchange (NYSE), raising a staggering USD 3.8 billion. This transaction has secured its place as the biggest IPO…
-
Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region
•
Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region of Belgium, with the aim of establishing a Good Manufacturing Practice (GMP)-compliant advanced radiopharmaceutical plant. This strategic move is set to bolster the company’s position in the radiation therapy sector. Addressing Manufacturing Challenges in Radiation…
-
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
•
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over the quarter. AstraZeneca’s China Innovation BoomAstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot warned that Europe is lagging behind China in fostering innovation and access to medicines. This statement came during the company’s Q1 2023 earnings…
-
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
•
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2) for intravitreal injection in the treatment…
-
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
•
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase I clinical trial of RV-1730, a SARS-CoV-2 vaccine booster candidate. Design of the Phase I Study for RV-1730The Phase I…
-
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
•
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital,…
-
Zai Lab Partners with MediLink Therapeutics to Develop YL212 DLL3 ADC
•
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688), a China-based biopharmaceutical company, has announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, a specialist in antibody drug conjugates (ADCs) founded in 2020. The agreement pertains to MediLink’s YL212, a novel DLL3 ADC program, highlighting Zai Lab’s commitment to…
-
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
•
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the National Medical Products Administration (NMPA) has accepted its market filing for vunakizumab, an IL-17A monoclonal antibody (mAb), for the treatment of moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy. Global IL-17A Products…
-
OBiO Technology and ImmVira Partner on Oncolytic Virus Project for BLA Filing and Commercialization
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading gene therapy specialist based in China, has entered into a partnership with fellow Chinese firm ImmVira. The collaboration pertains to the Biologics License Application (BLA) filing and the commercial industrialization of an oncolytic virus project. ImmVira, which is responsible for the…
-
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
•
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou, China, has announced the completion of first patient dosing in its Phase I clinical study for an investigational small interfering RNA (siRNA). This marks the first time such a therapy has entered the clinical phase…
-
CSPC Pharmaceutical Group Reports 11% YOY Revenue Growth in 2022 Financial Results
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its 2022 financial report, recording RMB 30.937 billion (USD 4.469 billion) in revenues, marking an 11% year-on-year (YOY) increase. The report details the performance of various business segments, with on-patent medicines generating RMB 24.52 billion (USD 3.5 billion, +10.8%), raw material…
-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
•
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first quarter of 2023, showing an 8% year-on-year (YOY) decrease in revenues in constant currency terms to GBP 6.95 billion (USD 8.67 billion). The decline is attributed to reduced demand for COVID-19 treatments, most notably the…
-
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
•
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III clinical study for the CD22 monoclonal antibody (mAb) SM03, also known as suciraslimab, has successfully reached the primary endpoint in patients with rheumatoid arthritis (RA). Study Design and Efficacy of SuciraslimabThe randomized, double-blind, multi-center, placebo-controlled…
-
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center, randomized, open, positive-controlled Phase III RENOTORCH study has reached pre-set endpoints at the interim analysis stage. The study evaluates the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with axitinib for the treatment of moderate to…
-
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical study for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has successfully reached the primary endpoint in patients with HR+/HER2- advanced breast cancer that has progressed after previous endocrine therapy combined with fulvestrant. Positive Mid-Term Analysis…
-
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a…
-
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market filing for the Category 1 drug prusogliptin, intended for the treatment of type 2 diabetes, has been accepted for review by the National Medical Products Administration (NMPA). Clinical Study Results and Efficacy of PrusogliptinA clinical…
-
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1 receptor-targeted drug, Zerviate (OT-1001), has been granted priority review status by the National Medical Products Administration (NMPA). Zerviate’s Origins and Market PresenceZerviate, originally developed by France-based pharmaceutical firm Nicox SA, is an innovative formulation of…
